Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B (Cert # L219170)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 08/25/2021
Content Release Date: 09/15/2021
Expiration Dates: 03/15/2022
Activity Type: Application-based
CE Credits: 8 contact hours
Activity Fee: $160 (ASHP member); $215 (non-member) 

Activity Overview

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.  

For full program information, please visit: http://rxcertifications.org

American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:

  • Breast Cancer
  • Gynecologic Malignancies
  • Hematopoietic Stem Cell Transplantation
  • Lung Cancer
  • Acute Leukemias and Myelodysplastic Syndrome
  • Lymphomas
  • Prostate Cancer

Board certified pharmacists are eligible to receive up to 8.0 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours

*Assessment Pass Point

Oncology Home Study Syllabus Module 2A: Breast Cancer, Gynecologic Malignancies, Hematopoietic Stem Cell Transplantation, Lung Cancer  

0204-9999-21-981-H01-P

4.00

76%

Oncology Home Study Syllabus Module 2B: Acute Leukemias and Myelodysplastic Syndrome, Lymphomas, Prostate Cancer

0204-9999-21-984-H01-P

4.00

75%

Please note, Board Certified Oncology Pharmacists must complete the Oncology Pharmacy Preparatory Review Course at least once, but no more than three times, in nonconsecutive years, during the 7-year recertification cycle.

Oncology Home Study Syllabus Module 2A: Breast Cancer, Gynecologic Malignancies, Hematopoietic Stem Cell Transplantation, Lung Cancer

ACPE #: 0204-9999-21-984-H01-P

Murthy RK, Loi S, Okines A et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
Learning Objectives:

  • Evaluate potential adverse effects and monitoring strategies for patients receiving tucatinib.
  • Summarize the efficacy and safety results of the HER2CLIMB trial.
  • Apply the results of the HER2CLIMB trial to patients with refractory HER2-positive metastatic breast cancer.

Ray-Coquard I, Pautier P, Pignata S et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019; 381(25):2416-28.
Learning Objectives:

  • Apply the findings of the PAOLA-1 trial to patients with newly diagnosed ovarian cancer.
  • Given patient-specific clinical data, develop therapeutic treatment and monitoring plans for patients with newly diagnosed ovarian cancer.
  • Summarize the adverse effect profile of the combination of olaparib and bevacizumab maintenance for patients with newly diagnosed ovarian cancer.

Zeiser R, von Bubnoff N, Butler J et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810.
Learning Objectives:

  • Evaluate the efficacy of ruxolitinib for treatment of glucocorticoid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation.
  • Counsel patients on toxicities of ruxolitinib when utilized for acute graft-versus-host disease.
  • Develop a therapeutic plan for glucocorticoid-refractory acute graft-versus-host disease based on the results of the REACH2 trial.

Wu YI, Tsuboi M, He J et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-23.

Wolf J, Seto T, Han JY et al. Capmatinb in MET exon 14-mutated or MET-amplified non-small cell lung cancer. N Engl J Med. 2020;383:944-57.
Learning Objectives:

  • Develop a patient-specific treatment, monitoring, and supportive care plan using recommendations from the ADAURA and GEOMETRY trials and current treatment guidelines for patients with non-small cell lung cancer.
  • Assess the efficacy and safety data of the ADAURA and GEOMETRY trials in reference to patients with non-small cell lung cancer.
  • Summarize the strengths and weaknesses of the design and methods used by the ADUARA trial.

Oncology Home Study Syllabus Module 2B: Acute Leukemias and Myelodysplastic Syndrome, Lymphomas, Prostate Cancer

ACPE #: 0204-9999-21-984-H01-P

Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399-1420.
Learning Objectives:

  • Design a patient-specific treatment, supportive care, and monitoring plan, taking into consideration recommendations from Garcia-Manero et al. and current treatment guidelines for adults with myelodysplastic syndrome.
  • Develop plans for preventing, monitoring, and treating adverse reactions from pharmacotherapy for myelodysplastic syndrome in an adult.
  • Select pharmacotherapy based on a diagnosis for myelodysplastic syndrome in an adult using genomic test results.

Shore ND, Saad F, Cookson MS et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187-2196.
Learning Objectives:

  • Apply the outcomes of the HERO study to the management of patients with prostate cancer.
  • Summarize the pharmacokinetic and pharmacodynamic properties of the novel oral agent, relugolix.
  • Given a patient case, evaluate the appropriateness of relugolix therapy for a patient with prostate cancer.

Poeschel V, Held G, Ziepert M et al.  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019; 394(10216):2271-2281.
Learning Objectives:

  • Interpret efficacy and safety data for two different treatment regimens in aggressive B-cell lymphoma.
  • Design a patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities, and outcomes for patients with aggressive B-cell lymphoma who receive four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab.
  • Assess the prognostic impact of cancer-related molecular biology testing.

Brette Conliffe, Pharm.D., BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky

Karen Fancher, Pharm.D., BCOP
Assistant Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania

Lauren Ice, Pharm.D., BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Janelle Mann, Pharm.D., BCOP
Manager, Oncology Clinical Pharmacy Services
Alvin J. Siteman Cancer Center
St. Louis, Missouri

Tim Peterson, Pharm.D., BCOP
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Perissinotti, Pharm.D., BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan

Danielle Roman, Pharm.D., BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Courtney C. Cavalieri, Pharm.D., BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah


Karen Fancher, Pharm.D., BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist–Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Danielle Roman, Pharm.D., BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Christine M. Walko, Pharm.D., BCOP, FCCP
Associate Member and Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
H. Lee Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida

Angela T. Cassano, Pharm.D., BCPS, FASHP
Susan R. Dombrowski, M.S., RPh

Nada Adel, BCOP, BCPS
Mohammed Alfar, BCOP
Pamiz Alibhai, Pharm.D., BCOP, MBA
Jonathan Angus, Pharm.D., BCOP
Mollie Beck, Pharm.D., BCOP
Patricia Bollendorf-Perez, BSPharm
Nicole Brunette, Pharm.D. BCPS BCOP
Yuliya Byakina, Pharm.D., BCOP
Kristian Casem, Pharm.D., BCOP
Susan Chacko, Pharm.D.
Zhi Yao Chan, BSc (Pharm), MClinPharm, BCOP
Tsz-Yi Chen, Pharm.D., BCPS, BCOP
Shih-Ying Cheng, BSpharm, BCOP
Kelly Chillari, Pharm.D., BCOP
Alan Chin, Pharm.D., BCOP
Krishna Rajasekar Chinnathurai, B.Pharm, BCOP
Matthew Chui, Pharm.D., BCOP
Tyler Crissinger, Pharm.D., BCOP
Laura Darland, Pharm.D., BCOP
Henry DeLu, Pharm.D., BCACP, BCOP
Rose DiMarco, Pharm.D., BCPS, BCOP
Tate Feeney, Pharm.D., BCOP
Lora Ferguson, Pharm.D., BCOP
Sarah Fillman, Pharm.D., BCPS, BCOP
Sara Gordon, Pharm.D., BCOP
Annie Ho, Pharm.D., BCOP
Jerline Hsin, Pharm.D., BCPS, BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Natalie Kamiyama, Pharm.D., BCOP
Katelyn Kammers, Pharm.D., BCPS, BCOP
Chris Kapolas, Pharm.D., BCOP
Stephen Kaurala, Pharm.D., BCOP
Erin Kelley, Pharm.D., BCOP
Elle Kim, BSPharm, BCOP, BCPS
Bonnie Labdi, Pharm.D., BCOP
Leslie LaMontagne, Pharm.D., BCOP
Matthew Lei, Pharm.D., BCOP
Jessica Lewis-Gonzalez, Pharm.D., BCOP
Yemag Limay, Pharm.D., BCOP
Pohung Lin, Pharm.D., BCOP, BCPS
Stephen Lirette, Pharm.D., BCPS, BCOP
Jacqueline Liu, Pharm.D., BCOP
Amanda Lucky, Pharm.D., BCPS, BCOP
Jillian Lykon, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Jillian Mancini, Pharm.D., BCOP
Sindhu Nair, Pharm.D., BCOP
Kim Nguyen, Pharm.D., BCOP
Eugene Okumyansky, Pharm.D., BCPS ,BCOP
Terry Pak, Pharm.D., BCOP
Apostolos Papachristos, Pharm.D., Ph.D., BCOP
Jooyoung Park, Pharm.D., BCOP
Jasmine Patel, Pharm.D., BCOP
Kinjal Patel, Pharm.D., BCOP
Pragna Patel, Pharm.D., BCOP
Mohammad Rattu, Pharm.D., BCOP, BCPS, BCGP
Forrest Ridgway, Pharm.D., BCPS, BCOP
Glenn Roma, Pharm.D., Ph.D., BCOP
Courtney Samuels, Pharm.D., BCOP
Eric Sansocie, Pharm.D., BCOP
Paula Sayegh, Pharm.D., BCPS, BCOP
Gianni Scappaticci, Pharm.D., BCOP
Kavita Sharma, Pharm.D., BCOP
Meenakshi Shelat, Pharm.D., BCOP
Anna Shook, Pharm.D., BCPS, BCOP
Phebe Si, Pharm.D., BCGP, BCOP
Bethany Sibbitt, Pharm.D., BCOP
Michael Singel, Pharm.D., BCPS, BCOP
Emily Tiao, Pharm.D., BCOP
Malgorzata Tyszka, B.Sc.Pharm, BCOP
Sorana Ursu, Pharm.D., BCOP
Amy VanGalder, Pharm.D., BCOP
Damaal Walker, Pharm.D., BCOP
Taylor Weis, Pharm.D., BCOP
Sarah Worth, Pharm.D., BCPS, BCOP
Jessie Yang, Pharm.D., BCOP
Wai Chung Yiu, MPharm, BCOP
Carolnn Yong, Pharm.D., BCPS, BCOP
Carrie Zhao, BCOP
Kelsey Zielke, Pharm.D., BCPS, BCOP
Jamie Ziggas, Pharm.D., BCOP

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen Fancher: Consultant, AstraZeneca, LP; Consultant, Merck & Co. 
  • Anthony Perissinotti: Consultant, Amgen; consultant, Pfizer; consultant, Servier
  • Tim Peterson: Advisory board consultant, GSK

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Development

These activities were developed by ASHP and ACCP.